140 related articles for article (PubMed ID: 7737258)
1. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
Iversen P
Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
3. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
Akaza H
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
5. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
Urologiia; 2001; (4):26-9. PubMed ID: 11569230
[TBL] [Abstract][Full Text] [Related]
6. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Kennealey GT; Furr BJ
Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
8. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
9. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.
Kaisary AV; Tyrrell CJ; Beacock C; Lunglmayr G; Debruyne F
Eur Urol; 1995; 28(3):215-22. PubMed ID: 8536775
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
Tyrrell CJ
Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
[TBL] [Abstract][Full Text] [Related]
11. [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer].
Kotake T; Usami M; Isaka S; Shimazaki J; Nakano E; Okuyama A; Okajima E; Kanetake H; Saitoh Y; Kumamoto Y; Orikasa S; Sakata Y; Hosaka M; Akaza H; Koiso K; Honma Y; Aso Y; Oishi K; Yoshida O; Naitoh S; Kumazawa J; Koyanagi T; Yachiku S; Shiraiwa Y; Tsukagoshi S
Hinyokika Kiyo; 1996 Feb; 42(2):157-68. PubMed ID: 8712092
[TBL] [Abstract][Full Text] [Related]
12. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
[TBL] [Abstract][Full Text] [Related]
13. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
14. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
[TBL] [Abstract][Full Text] [Related]
15. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
Blackledge GR
Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
[TBL] [Abstract][Full Text] [Related]
16. [Monotherapy with antiandrogens for prostatic cancer].
Sander S
Tidsskr Nor Laegeforen; 1999 Apr; 119(10):1451-3. PubMed ID: 10354754
[TBL] [Abstract][Full Text] [Related]
17. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
Tyrrell CJ
Prostate Suppl; 1992; 4():97-104. PubMed ID: 1574464
[TBL] [Abstract][Full Text] [Related]
18. Role of prostate-specific antigen as a predictor of outcome in prostate cancer.
Blackledge GR; Lowery K
Prostate Suppl; 1994; 5():34-8. PubMed ID: 7513530
[TBL] [Abstract][Full Text] [Related]
19. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
Mansueto G; Longo F
Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
